GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Source review / handoff

Tofersen intrathecal injection (QALSODY)

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

An RX mirror and its underlying label are not independent clinical confirmations.

Check source scope before reading a dose

QALSODY: renal pharmacokinetic evidence gap

Product / population
QALSODY tofersen injection, intrathecal use, adults with SOD1-associated amyotrophic lateral sclerosis. Specialist administration only.
Renal method
No renal dosing measure or validated renal adjustment in the selected PK passage.
Source revision
11/2025
Retrieved
2026-11-07
Local review status
Selected named renal sections summarized; not a complete monograph or independent clinician sign-off.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Not studied is not no adjustment

No renal or dialysis regimen is established by these selected PK statements; the mirror is older than the primary label.

What to reconcile: Use current specialist guidance and the complete exact-product label.

Selected-source comparison; independent clinician adjudication pending.

Open this note and its source references
Official

QALSODY: renal pharmacokinetic evidence gap

Open original reference

DailyMed / Biogen QALSODY label · QALSODY tofersen injection, intrathecal use, adults with SOD1-associated amyotrophic lateral sclerosis. Specialist administration only.

Renal method: No renal dosing measure or validated renal adjustment in the selected PK passage.
Source date: 11/2025
Retrieved: 2026-11-07

Limited or unstudied renal evidence. Not studied does not mean no adjustment is required.
Before using this finding

Confirm the exact product, indication, renal measure, kidney trend and dialysis modality.

Selected named renal sections summarized; not a complete monograph or independent clinician sign-off.

Selected renal instructions and limits

Dedicated pharmacokinetic studies in renal impairment have not been conducted. The selected label does not establish a renal adjustment or dialysis regimen. This is insufficient evidence, not proof that no adjustment is needed. Do not repurpose the intrathecal product for another route.

RDM70-tofersen-qalsody-1603e854fa · Source locator: Sections 1, 2.1 and 12.3

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=81356b45-1cb7-4eef-88ea-e44cc18b47c5
Retrieved
2026-11-07
Renal-function method
No renal dosing measure or validated renal adjustment in the selected PK passage.
Source date/version
11/2025
Hash meaning
Locally authored summary text; not original source HTML, XML or PDF bytes
Local summary SHA-256
1603e854fa74ce4bb4dd55aa43de0b2ef4bbdad0f99b6dd31151a26e9dcdab1b

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=tofersen-qalsody&s1=RDM70-tofersen-qalsody-label&h1=5ca26ba3da7d01d61034d7e5229a024074ea66eda371d62723bae9e51bfa7c5c

Top